sanostem

  • 1615 South Street, 93304

About Us

About Us

Shivinder S. Deol MD, ABAARM
CMO & COO, SanoStem
Dr. Randeep Singh Dhillon Ph.D.
CEO, SanoStem
Emails:

About Us

SanoStem: Transforming Health, Restoring Lives

Duniya SanoStem Inc (SanoStem) is a global biotechnology company that has acquired Stemedica Cell Technologies, Inc.(Stemedica)’s best-in-class allogeneic adult stem cells and stem cell factors. Stemedica is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based and global clinical trials. Stemedica has FDA Investigational New Drug Approvals for acute myocardial infarction, chronic heart failure, cutaneous photoaging, ischemic stroke, traumatic brain injury and Alzheimer’s disease.

SanoStem’s products are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. SanoStem is currently developing additional clinical trials for other medical indications using adult, allogeneic stem cell under the auspices of the FDA and other international regulatory agencies.

About Duniya SanoStem Inc (SanoStem)

Duniya SanoStem Inc (SanoStem), a Delaware Corporation, is a global regenerative company that promotes cell-based therapies to promote longevity, and quality of life, while reducing disability and diseases, especially for chronic stroke and other diseases that have no cure or treatment options. The company is headquartered in Bakersfield, California, and can be found online at www.sanostem.com
Team Members
0 +
Medical Instruments
0 +
Patient Satisfaction
0 +

Team

  1. To advance our exclusive technology, SanoStem has a group of skilled scientists, managers, and technicians.

Technology

Several progenitor cell products that satisfy the strict quality requirements needed for a CGMP-licensed facility are produced using SanoStem’s proprietary platform technology.

Trials

In the US, SanoStem is now progressing clinical studies for a number of serious illnesses.

Executive Team

Dr. Randeep Singh Dhillon Ph.D.
CEO, SanoStem

Mr. Vishal Ralahan

COO, SanoStem

Mr. Gurjit Singh

CFO, SanoStem

Scientific Medical Advisory Board

Dr. Alexander Kharazi MD, PhD
Chief Technology Officer

Dr. Duke Multani MD
Chief Research Officer

Dr. Daniyar Jumaniyazov MD, Ph.D.
Principal Investigator, KZ

About Us

SanoMSC: Transforming Health, Restoring Lives.

Sanostem Cell Technologies, Inc. is a clinical-stage biopharmaceutical business that specializes in the creation and marketing of protein and progenitor cell therapies for undertreated illnesses. In a cGMP-compliant production facility, Sanostem has created a patented manufacturing technology platform that generates allogeneic progenitor cell products with intellectual property protection in a low-oxygen, low-tension setting. Ischemia-tolerant mesenchymal stem cells, or itMSCs, are the company’s top medication candidate. They are an allogeneic progenitor cell therapy that is presently undergoing clinical development to treat Alzheimer’s disease and ischemic stroke. Ischemia-tolerant neural progenitor cells, or itNSCs, are the company’s second therapeutic candidate.
They are an allogeneic cell treatment that is presently being developed for spinal cord injury. Sanostem is also working on progenitor cell and protein combination therapy for Alzheimer’s disease and progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke.

Team

To advance our exclusive technology, Sanostem has a group of skilled scientists, managers, and technicians.

Technology

Several progenitor cell products that satisfy the strict quality requirements needed for a CGMP-licensed facility are produced using Sanostem’s proprietary platform technology.

Trials

In the US, Sanostem is now progressing clinical studies for a number of serious illnesses.
Scroll to Top